NCT04556617: PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
|
|
| Terminated | 1b/2a | 19 | Europe, US | PLX2853, Olaparib, Abiraterone acetate, Prednisone | Opna-IO LLC | Metastatic Castration-resistant Prostate Cancer | 05/22 | 05/22 | | |
2020-002021-28: A Study to Evaluate PLX2853 in Combination with Abiraterone Acetate/Prednisone and PLX2853 in Combination with Olaparib in Subjects with Metastatic Castration-Resistant Prostate Cancer |
|
|
| Not yet recruiting | 1/2 | 110 | Europe | PLX2853, Abiraterone Acetate, Prednisolone, PLX2853, Tablet, ZYTIGA, PREDNISOLONE | Plexxikon Inc., Plexxikon Inc. | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer, Diseases [C] - Cancer [C04] | | | | |
NCT05677373: Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma |
|
|
| Withdrawn | 1/2 | 54 | NA | BRD4 Inhibitor PLX2853, PLX 2853, PLX-2853, PLX2853, Trametinib, 871700-17-3, GSK1120212, JTP-74057, Computed Tomography, CAT, CAT scan, Computed Axial Tomography, CT Scan, Magnetic Resonance Imaging, MRI, Biospecimen collection | Alliance for Clinical Trials in Oncology | Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma | 07/25 | 07/25 | | |
